An Early Phase 1 interventional study of Inhaled Melatonin (100 μg) and Oral Melatonin (4 mg) in Insomnia, sponsored by Woolcock Institute of Medical Research. Recruiting at 1 site in Australia. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2025-07-18.
Sponsored by Woolcock Institute of Medical Research · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing melatonin in Sleep Initiation and Maintenance Disorders — 8 open to participants now, 8 under way, 2 of them phase 3. Melatonin · Sleep Initiation and Maintenance Disorders.
Among the 25 studies testing melatonin in Sleep Initiation and Maintenance Disorders, this one is the 22nd largest by planned enrollment, is one of 4 that started in 2025, is one of 3 in phase 1, and was the 19th registered.
2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →8 of the 25 studies testing melatonin in Sleep Initiation and Maintenance Disorders are open now, in 6 countries. Recruiting first, the newest first:
The University of Hong Kong · Sites in Hong Kong
Ages 60+
Emory University · Sites in United States
Ages 18–65
Weill Medical College of Cornell University · Sites in United States
Ages 18+
Woolcock Institute of Medical Research · Sites in Australia
Ages 55+
Mahidol University · Sites in Thailand
Ages 18+
By country, each count listing its studies:
Melatonin: first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 6 · Phase 4 3
First in 1995; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 68 across 2,356 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 59 across the 25 interventional studies. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 25 have an industry lead sponsor. The 10 most frequent:
Woolcock Institute of Medical Research is the lead sponsor of 17 studies on the registry; 12 are open to participants now.
10 studies in Sleep Initiation and Maintenance Disorders by Woolcock Institute of Medical Research: 7 open now, 7 under way, none of them phase 3. Of 3 finished, 0 (0%) have results posted.
Among the 10 studies in Sleep Initiation and Maintenance Disorders by Woolcock Institute of Medical Research, this one is the 9th largest by planned enrollment, is one of 4 that started in 2025, is one of 2 in phase 1, and was the 6th registered.
Woolcock Institute of Medical Research’s Sleep Initiation and Maintenance Disorders studies by the year they started, since 2022.
3 of the studies testing melatonin in Sleep Initiation and Maintenance Disorders that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07336277Phase 3Emory UniversitySleep Quality and the Efficacy of a Multimodal Sleep Pathway in Hospitalized Orthopedic Trauma Patients | 2027-07 |
| NCT07046429Weill Medical College of Cornell UniversityAffect of Melatonin on Sleep and Cognition in Cirrhosis | 2026-12-31 |
| NCT07737665Mahidol UniversityEfficacy of Melatonin Treatment on Sleep Quality Improvement in Inflammatory Bowel Disease Patients With Clinical Remission | 2027-04-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 25 studies testing melatonin in Sleep Initiation and Maintenance Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Woolcock Institute of Medical Research’s 10 in Sleep Initiation and Maintenance Disorders:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to explore the potential benefits of an inhaled version of melatonin compared to oral melatonin tablets on adults with insomnia. The main question the trial aims to answer is: does inhaled melatonin affect the sleep profiles of adults with insomnia differently than oral melatonin tablets?
10 Participants will:
This is a randomised open-label cross-over study of an inhaled formulation of melatonin (100 µg) versus oral melatonin tablets (4 mg) in adults with insomnia. The experiments performed for this trial will examine the effects of inhaled and oral melatonin on sleep microarchitecture such as sleep onset latency.
To be enrolled in the trial, participants are required to complete an online pre-screening survey. Eligible participants will be directed to a separate webpage where they will be invited to review and download the Participant Information Sheet (PIS) and asked to provide their contact details and consent for a follow up call/email from the research team to book in a screening visit. At the screening visit, the study team will explain the study to each participant and provide the opportunity to ask any questions. The study team will also ensure participants have had ample time prior to the visit to read and understand the PIS. The consent form will be signed by both the participant and a medical officer and participants. Once participants have joined the efficacy study, they will be randomised into their first treatment group; inhaled melatonin (100 µg) or oral melatonin tablets (4 mg).
Participants will attend the laboratory for an overnight visit then be treated with either inhaled melatonin or oral melatonin tablets before completing an overnight polysomnography sleep study. After the sleep study, participants will continue to take the study drug every night for two weeks and complete a sleep diary each morning to assess participant subjective perception of sleep quality. Once the two weeks of treatment have been completed, participants will visit the laboratory again to provide a blood sample that will be examined for biomarkers of neuroinflammation. There will be a 1 week washout period between treatment periods.
The study will recruit primarily through social media advertisements. The study will be coordinated from the Woolcock Institute of Medical Research, Sydney, Macquarie University, NSW, 2113, Australia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
100 µg daily of inhaled melatonin delivered by pressurized metered dose inhaler for two weeks before habitual bedtime.
Drug: Inhaled Melatonin (100 μg)
4 mg daily of orally delivered melatonin tablets for two weeks before habitual bedtime.
Drug: Oral Melatonin (4 mg)
An orally inhaled formulation of melatonin delivered by pressurised metered dose inhaler (pMDI) to be taken before bedtime. The pMDI will deliver a total of 100 μg of inhaled melatonin (2 x 50 μg/actuation). The investigational product is produced under Good Manufacturing Practice by Ab Initio Pharma Pty Ltd, a GMP certified manufacturer of pharmaceutical products.
Also known as: Melatonin
Two orally ingested tablets each containing 2 mg of melatonin (4 mg total) to be taken before bedtime. The investigational product is manufactured under Good Manufacturing Practice and is compliant with the TGA Therapeutic Order #101 that stipulates quality control requirements for capsule and pill-based products used in Australia.
Also known as: N-Acetyl-5-methoxytryptamine, Circadin, Melatonin
Sleep onset latency
Sleep onset latency (minutes) as assessed by polysomnography (PSG) on the first night of therapy. Sleep onset latency is the time between lights out and the first 30 second epoch scored as sleep using the American academy of sleep medicine criteria.
Time frame: Day 1
Insomnia Severity Index
The Insomnia Severity Index (ISI) is a 7-item questionnaire used to examine overall insomnia severity. It consists of a five-point Likert type scale for each item (ranging from "no problem" = 0 to "severe problem" = 28) regarding symptoms over the past 2 weeks. Scores range from 0-28 with higher scores indicating greater insomnia symptom severity.
Time frame: Measured during the initial screening visit and day 14 of treatment.
Wake after sleep onset
Wake after sleep onset (WASO) is measured in minutes and is calculated from the first epoch of any sleep detected on the polysomnogram until the last epoch of sleep detected on the polysomnogram.
Time frame: Day 1
Total sleep time
Total sleep time (TST) is measured in minutes and is the sum of all 30 second epochs scored as sleep during an overnight polysomnogram.
Time frame: Day 1
Participant perception of sleep quality
Ordinal rating of sleep quality (How would you rate the quality of your sleep? 9 = best ever sleep, 5 = neither best nor worst sleep, 1 = worst sleep ever), assessed in the Karolinska sleep diary after waking every day for two weeks.
Time frame: Every observation for two weeks
Traditional sleep staging
Proportion of the sleep opportunity scored at the 5 stages (wake, and N1, N2, N3, and REM sleep) between lights out and lights on, measured using overnight in-laboratory polysomnography, scored by a polysomnography technician in accordance with AASM Sleep Scoring criteria.
Time frame: Day 1
Absolute Electroencephalography (EEG) Power During Non-Rapid Eye Movement (NREM) Sleep
Spectral power of low delta (0.5-1 Hz), delta (1-4.5 Hz), theta (4.5-8 Hz), alpha (8-12 Hz), sigma (12-15 Hz), beta (15-25 Hz), and gamma (25-40 Hz) frequency ranges between treatment arms. Power spectral analysis will be applied to EEG signals from polysomnography during NREM sleep after artefacts are detected and removed.
Time frame: Day 1
Absolute Electroencephalography (EEG) Power During Rapid Eye Movement (REM) Sleep
Spectral power of low delta (0.5-1 Hz), delta (1-4.5 Hz), theta (4.5-8 Hz), alpha (8-12 Hz), sigma (12-15 Hz), beta (15-25 Hz), and gamma (25-40 Hz) frequency ranges between treatment arms. Power spectral analysis will be applied to EEG signals from polysomnography during REM sleep after artefacts are detected and removed.
Time frame: Day 1
Blood levels of glial fibrillary acidic protein
Blood-based glial fibrillary acidic protein (GFAP) within each participant, as measured by SIMOA blood neuro-metabolite assay.
Time frame: Day 14 of treatment.
Blood levels of interleukin-6
Blood-based interleukin-6 (IL-6), as measured by SIMOA blood neuro-metabolite assay.
Time frame: Day 14 of treatment.
Blood levels of plasma tau
Blood-based plasma tau within each participant, as measured by SIMOA blood neuro-metabolite assay.
Time frame: Day 14 of treatment.
Blood levels of granulocyte-macrophage colony-stimulating factor
Blood-based granulocyte-macrophage colony-stimulating factor (GM-CSF) within each participant, as measured by SIMOA blood neuro-metabolite assay.
Time frame: Day 14 of treatment.
Blood levels of brain derived neurotrophic factor
Blood-based brain derived neurotrophic factor (BDNF) within each participant, as measured by SIMOA blood neuro-metabolite assay.
Time frame: Day 14 of treatment.
Blood levels of neurofilament light chain
Blood-based neurofilament light chain (NFL) within each participant, as measured by SIMOA blood neuro-metabolite assay.
Time frame: Day 14 of treatment.
Blood levels of amyloid β (Aβ)
Blood-based Aβ (Aβ40:Aβ42 ratio) within each participant, as measured by SIMOA blood neuro-metabolite assay.
Time frame: Day 14 of treatment.
Blood levels of C-reactive protein
Blood-based C-reactive protein (CRP) within each participant, as measured by SIMOA blood neuro-metabolite assay.
Time frame: Day 14 of treatment.
Plan to share: Yes — Non-identifiable IPD will be shared upon reasonable request to the Principal Investigators.
Time frame: Non-identifiable IPD will become available one year after the Actual Study Completion Date and will remain available for fifteen years.
Access criteria: Following Macquarie University access terms, access restrictions will be limited to appropriate permission, project proposal and approved from the investigator team and data custodian. Any Recipients of the data must obtain project and HREC approval prior to mediated access. The Coordinating Principal Investigator, Dr. Hui Xin Ong, will be retain access the de-identified data, stored on the Macquarie University Research Data Repository (RDR).
Data sharing details ↗ · libguides.mq.edu.au
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Dec 2025, 5 months after the start.
Of 39 phase 1 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's planned 5 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Melatonin
Sleep Initiation and Maintenance Disorders →
Woolcock Institute of Medical Research